Farnesyltransferase Inhibitors Progeria
Jan. 11, 2025
Lonafarnib Pre-clinical Drug Supply Program | The Progeria Research Foundation A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model | PNAS Frontiers | Bacteria Are New Targets for Inhibitors of Human Farnesyltransferase Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome | Circulation | Farnesyltransferase Inhibitors Progeria
![PDF] Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA…](https://d3i71xaburhd42.cloudfront.net/522530d3ab1284f091f2c9e7b0606dadbef01090/43-Figure4-1.png){kind=link}
![PDF] Intermittent treatment with farnesyltransferase inhibitor and sulforaphane imp…](https://d3i71xaburhd42.cloudfront.net/bda0bbec873183a4e57dd94fff8ba9c21f65491c/12-Figure6-1.png){kind=link}
![PDF] Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads t…](https://d3i71xaburhd42.cloudfront.net/01e46d70c41edaa17ea1d3c7f3f3c68425249409/3-Figure1-1.png){kind=link}
